Abbott Laboratories vs Stryker
Add, change or remove companies; up to four.
The short version
- Abbott Laboratories is the larger business, with $44.3B of revenue in fiscal 2025 against $25.1B for Stryker, about 1.8 times as much.
- Stryker grew revenue faster (11.2%, against 5.7%).
- Stryker kept more of each dollar of sales as operating profit (19.5% operating margin, against 18.2%).
- Investors pay more for each dollar of Stryker’s earnings: a P/E of 31.8x against 29.0x for Abbott Laboratories.
| Latest fiscal year | ABT · FY25 | SYK · FY25 |
|---|---|---|
| Size | ||
| Market cap | $181.2B | $118.6B |
| Revenue | $44.3B | $25.1B |
| Free cash flow | $7.4B | $4.3B |
| Net income | $6.5B | $3.2B |
| Growth | ||
| Revenue growth | 5.7% | 11.2% |
| 5-year growth | 5.1% | 11.8% |
| Share count change | 0.0% | 0.2% |
| Profitability | ||
| Gross margin | 56.4% | 64.0% |
| Operating margin | 18.2% | 19.5% |
| Net margin | 14.7% | 12.9% |
| FCF margin | 16.7% | 17.1% |
| Return on capital | 11.2% | 11.3% |
| Return on equity | 13.1% | 15.1% |
| Balance sheet | ||
| Net debt | $4.0B | $10.8B |
| Net debt / EBITDA | 0.4x | 1.7x |
| Dividends and buybacks | $5.0B | $1.3B |
| Valuation & quality | ||
| P/E | 29.0x | 31.8x |
| Piotroski F-score | 6 | 6 |
Revenue
FY16
ABT $20.9B
SYK $11.3B
FY17
ABT $27.4B
SYK $12.4B
FY18
ABT $30.6B
SYK $13.6B
FY19
ABT $31.9B
SYK $14.9B
FY20
ABT $34.6B
SYK $14.4B
FY21
ABT $43.1B
SYK $17.1B
FY22
ABT $43.7B
SYK $18.4B
FY23
ABT $40.1B
SYK $20.5B
FY24
ABT $42.0B
SYK $22.6B
FY25
ABT $44.3B
SYK $25.1B
ABT
SYK
Operating margin
FY16
ABT 14.5%
SYK 19.2%
FY17
ABT 5.7%
SYK 18.5%
FY18
ABT 11.9%
SYK 18.7%
FY19
ABT 14.2%
SYK 18.2%
FY20
ABT 15.5%
SYK 15.5%
FY21
ABT 19.6%
SYK 15.1%
FY22
ABT 19.2%
SYK 15.4%
FY23
ABT 16.2%
SYK 19.0%
FY24
ABT 16.3%
SYK 16.3%
FY25
ABT 18.2%
SYK 19.5%
ABT
SYK
Free cash flow
FY16
ABT $2.1B
SYK $1.4B
FY17
ABT $4.4B
SYK $961M
FY18
ABT $4.9B
SYK $2.0B
FY19
ABT $4.5B
SYK $1.5B
FY20
ABT $5.7B
SYK $2.8B
FY21
ABT $8.6B
SYK $2.7B
FY22
ABT $7.8B
SYK $2.0B
FY23
ABT $5.1B
SYK $3.1B
FY24
ABT $6.4B
SYK $3.5B
FY25
ABT $7.4B
SYK $4.3B
ABT
SYK
Return on capital
FY16
ABT 9.5%
SYK 17.4%
FY17
ABT 2.1%
SYK 8.5%
FY18
ABT 6.2%
SYK 16.6%
FY19
ABT 9.0%
SYK 12.5%
FY20
ABT 10.7%
SYK 8.7%
FY21
ABT 16.4%
SYK 9.5%
FY22
ABT 16.0%
SYK 9.8%
FY23
ABT 12.4%
SYK 12.7%
FY24
ABT 13.6%
SYK 11.4%
FY25
ABT 11.2%
SYK 11.3%
ABT
SYK
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.